A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors (NCT07066657)
An Open-Label, Multi-Center, Dose Escalation, Confirmation, and Expansion Phase I Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of MRG007 (ARR-217) in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
This is an open-label, multi-center, phase I study to evaluate the safety, tolerability, efficacy, and pharmacokinetics of MRG007 (ARR-217) in patients with unresectable locally advanced or metastatic solid tumors.
Who can join: Review the eligibility criteria below.
Location: ULCA — Los Angeles, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (21 Sites)
- ULCA — Los Angeles, California
- UCSF — San Francisco, California
- University of Colorado — Aurora, Colorado
- Sarah Cannon Research Institute — Denver, Colorado
- Sarah Cannon Research Institute — Sarasota, Florida
- Sarah Cannon Research Institute — Nashville, Tennessee
- MD Anderson Cancer Center — Houston, Texas
- NEXT Dallas — Irving, Texas
- NEXT Virginia — Fairfax, Virginia
- Fred Hutchinson Cancer Center — Seattle, Washington
- Peking University Cancer Hospital — Beijing, Beijing Municipality
- Beijing Gobroad Hospital — Beijing, Beijing Municipality
- Chongqing Daping Hospital — Chongqing, Chongqing Municipality
- Sir Run Run Shaw Hospital, Zhejiang University School of Medicine — Zhejiang, Hangzhou
- Harbin Medical University Cancer Hospital — Heilongjiang, Harbin
- Henan Cancer Hospital — Zhengzhou, Henan
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology — Wuhan, Hubei
- Hunan Cancer Hospital — Changsha, Hunan
- Cancer Hospital of Shandong First Medical University — Shandong, Jinan
- Renji Hospital Shanghai Jiaotong University School of Medicine — Shanghai, Shanghai Municipality
- Zhongshan Hospital Fudan University — Shanghai, Shanghai Municipality
📞 Contact the Study Coordinator
Phone: (888) 622-2827
Email: ClinicalTrials.gov@ArriVent.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Locally Advanced or Metastatic Solid Tumors
- A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors — San Francisco, California
- PTT-936 Alone or in Combination in Patients With Locally Advanced or Metastatic Solid Tumors — Beverly Hills, California
- A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors — San Diego, California
- Study of XB010 in Subjects With Solid Tumors — Irvine, California
Explore by condition: All Locally Advanced or Metastatic Solid Tumors clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.